• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Incyte Corp.

    6/18/25 4:02:42 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email
    S-8 1 tm2517983d2_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 18, 2025.

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    INCYTE CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware   94-3136539
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)
         

    1801 Augustine Cut-Off

    Wilmington, Delaware

      19803
    (Address of Principal Executive Offices)   (Zip Code)
         

    1997 EMPLOYEE STOCK PURCHASE PLAN OF

    INCYTE CORPORATION

    (Full title of the plan)

         
    HERVÉ HOPPENOT   Copy to:
    President and Chief Executive Officer   STANTON D. WONG
    Incyte Corporation   Pillsbury Winthrop Shaw Pittman LLP

    1801 Augustine Cut-Off

    Wilmington, Delaware

    (302) 498-6700

     

    Four Embarcadero Center, 22nd Floor

    San Francisco, California 94111

    (415) 983-1000

    (Name, address and telephone number,

    including area code, of agent for service)

       

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x   Accelerated filer ¨                 

    Non-accelerated filer ¨

    (Do not check if a smaller reporting company)

     

    Smaller reporting company ¨

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

    PART I

     

    INFORMATION REQUIRED PURSUANT

    TO GENERAL INSTRUCTION E TO FORM S-8

     

    General Instruction E Information

     

    This registration statement (the “Registration Statement”) is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of Incyte Corporation (the “Registrant”) on Form S-8 relating to the same employee benefit plan is effective.

     

    The Registrant’s Form S-8 Registration Statements filed with the Securities and Exchange Commission on July 16, 1997 (File No. 333-31409), October 3, 2000 (File No. 333-47180), August 15, 2001 (File No. 333-67596), June 28, 2002 (File No. 333-91540), August 15, 2003 (File No. 333-108013), May 25, 2006 (File No. 333-134472), June 17, 2008 (File No. 333-151715), June 16, 2009 (File No. 333-160007), June 15, 2010 (File No. 333-167528), June 15, 2011 (File No. 333-174919), June 17, 2016 (File No. 333-212102), June 15, 2020 (File No. 333-239162), and June 30, 2023 (333-273056) are hereby incorporated by reference.

     

    Part II

     

    Information Required in the Registration Statement

     

    Item 3.Incorporation of Documents by Reference.

     

    The following documents previously filed by Registrant with the Securities and Exchange Commission are hereby incorporated by reference in this Registration Statement:

     

    (1)Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024;

     

    (2)Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025;

     

    (3)Registrant’s Current Reports on Form 8-K filed on January 10, 2025, May 14, 2025 and June 11, 2025; and

     

    (4)The description of the Common Stock contained in Registrant’s Registration Statement on Form 8-A filed January 5, 1996.

     

    In addition, all documents subsequently filed by Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. The Registrant is not, however, incorporating, in each case, any documents or information that the Registrant is deemed to furnish and not file in accordance with Securities and Exchange Commission rules.

     

    Any statement contained in this Registration Statement or in a document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any subsequently filed document that is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such statement.

     

    - 1 -

     

    Item 8.Exhibits

     

    Exhibit  
    Number Exhibit
       
    5.1 Opinion of Pillsbury Winthrop Shaw Pittman LLP.
       
    23.1 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
       
    23.2 Consent of Pillsbury Winthrop Shaw Pittman LLP (included in Exhibit 5.1).
       
    24.1 Power of Attorney (included on the signature page hereto).
       
    107.1 Calculation of Filing Fee Tables

     

    - 2 -

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington, State of Delaware, on June 18, 2025.

     

      INCYTE CORPORATION
       
      By /s/ Hervé Hoppenot
        Hervé Hoppenot
        President and Chief Executive Officer
        (Principal Executive Officer)

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Hervé Hoppenot, Christiana Stamoulis, and Sheila Denton, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated:

     

    Signature   Title   Date
             
    /s/ Hervé Hoppenot   President and Chief Executive Officer   June 18, 2025
    Hervé Hoppenot     (Principal Executive Officer) and Chairman    
             
    /s/ Christiana Stamoulis     Executive Vice President and Chief Financial Officer   June 18, 2025
    Christiana Stamoulis   (Principal Financial Officer)    
             
    /s/ Thomas R. Tray   Vice President and Chief Accounting Officer   June 18, 2025
    Thomas R. Tray     (Principal Accounting Officer)    
             
    /s/ Julian C. Baker   Director   June 18, 2025
    Julian C. Baker        
             
    /s/ Jean-Jacques Bienaimé   Director   June 18, 2025
    Jean-Jacques Bienaimé        
             
    /s/ Otis W. Brawley   Director   June 18, 2025
    Otis W. Brawley        
             
    /s/ Paul J. Clancy   Director   June 18, 2025
    Paul J. Clancy        
             
    /s/ Jacqualyn A. Fouse   Director   June 18, 2025
    Jacqualyn A. Fouse        
             
    /s/ Edmund P. Harrigan   Director   June 18, 2025
    Edmund P. Harrigan        
             
    /s/ Katherine A. High   Director   June 18, 2025
    Katherine A. High        
             
    /s/ Susanne Schaffert   Director   June 18, 2025
    Susanne Schaffert        

     

    - 3 -

     

    Get the next $INCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    9/18/2024$83.00 → $74.00Buy → Hold
    Truist
    7/2/2024$52.00 → $48.00Market Perform → Underperform
    BMO Capital Markets
    More analyst ratings

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

      QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) and Incyte (NASDAQ:INCY) today announced a ne

      6/15/25 4:00:00 AM ET
      $ILMN
      $INCY
      $QGEN
      Medical Specialities
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

      Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

      6/15/25 3:15:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

      POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global

      6/12/25 6:45:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

      9/28/21 5:20:01 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

      9/23/21 5:11:12 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for OPZELURA issued to INCYTE CORP

      Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      9/22/21 11:16:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brawley Otis W was granted 2,518 shares, increasing direct ownership by 29% to 11,252 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      6/12/25 4:31:17 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Fouse Jacqualyn A was granted 2,518 shares, increasing direct ownership by 15% to 19,326 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      6/12/25 4:30:47 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Bienaime Jean Jacques was granted 2,518 shares, increasing direct ownership by 14% to 20,841 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      6/12/25 4:30:12 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care